| " The contents of this blog are for informational purposes only and should not be construed as medical advice or substitute for professional care. For medical emergencies, dial 911!" "Only about 5 percent of patients with pancreatic cancer are still alive five years after being diagnosed." "When you enter your name and email address, you'll be sent a link to confirm your comment, and a password. To leave another comment, just use that password." "To create a live link, simply type the URL (including http://) or email address and we will make it a live link for you. You can put up to 3 URLs in your comments. Line breaks and paragraphs are automatically converted ? no need to use or
tags." "ImClone Systems Inc.'s drug Erbitux has failed to help pancreatic cancer patients live longer. It's also failed to grow ImClone's market -- not surprising since it's the company's only drug." "Imclone, partnering with Bristol-Myers Squibb Co., wanted to see Erbitux -- already cleared for use with colon, head, and neck cancers -- extend the lives of patients with cancer marked by a spread to the pancreas." "No one is giving up just yet, and Imclone plans additional tests on Erbitux's use in pancreatic cancer. A study
... read the whole article |